Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:18221492rdf:typepubmed:Citationlld:pubmed
pubmed-article:18221492lifeskim:mentionsumls-concept:C0086418lld:lifeskim
pubmed-article:18221492lifeskim:mentionsumls-concept:C0014436lld:lifeskim
pubmed-article:18221492lifeskim:mentionsumls-concept:C0022478lld:lifeskim
pubmed-article:18221492lifeskim:mentionsumls-concept:C0030940lld:lifeskim
pubmed-article:18221492lifeskim:mentionsumls-concept:C0215993lld:lifeskim
pubmed-article:18221492lifeskim:mentionsumls-concept:C1879547lld:lifeskim
pubmed-article:18221492pubmed:issue5lld:pubmed
pubmed-article:18221492pubmed:dateCreated2008-2-26lld:pubmed
pubmed-article:18221492pubmed:abstractTextHepatocyte growth factor activator (HGFA) is a serine protease and a potent activator of prohepatocyte growth factor/scatter factor (pro-HGF/SF), a multifunctional growth factor that is critically involved in tissue morphogenesis, regeneration, and tumor progression. HGFA circulates as a zymogen (pro-HGFA) and is activated in response to tissue injury. Although thrombin is considered to be an activator of pro-HGFA, alternative pro-HGFA activation pathways in tumor microenvironments remain to be identified. In this study, we examined the effects of kallikrein 1-related peptidases (KLKs), a family of extracellular serine proteases, on the activation of pro-HGFA. Among the KLKs examined (KLK2, KLK3, KLK4 and KLK5), we identified KLK4 and KLK5 as novel activators of pro-HGFA. Using N-terminal sequencing, the cleavage site was identified as the normal processing site, Arg407-Ile408. The activation of pro-HGFA by KLK5 required a negatively charged substance such as dextran sulfate, whereas KLK4 could process pro-HGFA without dextran sulfate. KLK5 showed more efficient pro-HGFA processing than KLK4, and was expressed in 50% (13/25) of the tumor cell lines examined. HGFA processed by these KLKs efficiently activated pro-HGF/SF, and led to cellular scattering and invasion in vitro. The activities of both KLK4 and KLK5 were strongly inhibited by HGFA inhibitor type 1, an integral membrane Kunitz-type serine protease inhibitor that inhibits HGFA and other pro-HGF/SF-activating proteases. These data suggest that KLK4 and KLK5 mediate HGFA-induced activation of pro-HGF/SF within tumor tissue, which may thereafter trigger a series of events leading to tumor progression via the MET receptor.lld:pubmed
pubmed-article:18221492pubmed:languageenglld:pubmed
pubmed-article:18221492pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18221492pubmed:citationSubsetIMlld:pubmed
pubmed-article:18221492pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18221492pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18221492pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18221492pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18221492pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18221492pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18221492pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18221492pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18221492pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18221492pubmed:statusMEDLINElld:pubmed
pubmed-article:18221492pubmed:monthMarlld:pubmed
pubmed-article:18221492pubmed:issn1742-464Xlld:pubmed
pubmed-article:18221492pubmed:authorpubmed-author:NakaDaijiDlld:pubmed
pubmed-article:18221492pubmed:authorpubmed-author:TanakaHiroyuk...lld:pubmed
pubmed-article:18221492pubmed:authorpubmed-author:KataokaHiroak...lld:pubmed
pubmed-article:18221492pubmed:authorpubmed-author:OsadaYukioYlld:pubmed
pubmed-article:18221492pubmed:authorpubmed-author:FukushimaTsuy...lld:pubmed
pubmed-article:18221492pubmed:authorpubmed-author:MukaiShoichir...lld:pubmed
pubmed-article:18221492pubmed:issnTypePrintlld:pubmed
pubmed-article:18221492pubmed:volume275lld:pubmed
pubmed-article:18221492pubmed:ownerNLMlld:pubmed
pubmed-article:18221492pubmed:authorsCompleteYlld:pubmed
pubmed-article:18221492pubmed:pagination1003-17lld:pubmed
pubmed-article:18221492pubmed:meshHeadingpubmed-meshheading:18221492...lld:pubmed
pubmed-article:18221492pubmed:meshHeadingpubmed-meshheading:18221492...lld:pubmed
pubmed-article:18221492pubmed:meshHeadingpubmed-meshheading:18221492...lld:pubmed
pubmed-article:18221492pubmed:meshHeadingpubmed-meshheading:18221492...lld:pubmed
pubmed-article:18221492pubmed:meshHeadingpubmed-meshheading:18221492...lld:pubmed
pubmed-article:18221492pubmed:meshHeadingpubmed-meshheading:18221492...lld:pubmed
pubmed-article:18221492pubmed:meshHeadingpubmed-meshheading:18221492...lld:pubmed
pubmed-article:18221492pubmed:meshHeadingpubmed-meshheading:18221492...lld:pubmed
pubmed-article:18221492pubmed:year2008lld:pubmed
pubmed-article:18221492pubmed:articleTitleActivation of hepatocyte growth factor activator zymogen (pro-HGFA) by human kallikrein 1-related peptidases.lld:pubmed
pubmed-article:18221492pubmed:affiliationSection of Oncopathology and Regenerative Biology, Department of Pathology, Faculty of Medicine, University of Miyazaki, Japan.lld:pubmed
pubmed-article:18221492pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:18221492pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
entrez-gene:3083entrezgene:pubmedpubmed-article:18221492lld:entrezgene
entrez-gene:9622entrezgene:pubmedpubmed-article:18221492lld:entrezgene
entrez-gene:25818entrezgene:pubmedpubmed-article:18221492lld:entrezgene
http://linkedlifedata.com/r...entrezgene:pubmedpubmed-article:18221492lld:entrezgene
http://linkedlifedata.com/r...entrezgene:pubmedpubmed-article:18221492lld:entrezgene
http://linkedlifedata.com/r...entrezgene:pubmedpubmed-article:18221492lld:entrezgene
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:18221492lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:18221492lld:pubmed